Home LiteratureArticle Details
PMID: 7298846 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Sulfation of lithocholate as a possible modifier of chenodeoxycholic acid-induced elevations of serum transaminase in patients with gallstones.

The Journal of clinical investigation ·Vol. 68 ·No. 5 ·1981-11-00 ·Pages 1190-6

Marks JW, Sue SO, Pearlman BJ, Bonorris GG, Varady P, Lachin JM, Schoenfield LJ

Abstract

Chenodeoxycholic acid (CDC), through its metabolite, lithocholic acid (LC), is hepatotoxic in certain species. The cause of elevations of serum transaminase in 25% of humans ingesting CDC, however, is unknown, but also may be due to LC. Because efficient hepatic sulfation of LC may protect against hepatic injury, the aim of this study was to determine if sulfation of LC might modify CDC-induced elevations of transaminase. Pretreatment sulfation fraction (SF) was estimated in 63 randomly selected patients with gallstones in a double-blind randomized trial of CDC, 750 mg/d, 375 mg/d, or placebo; in 27 of these, SF was repeated at 1 or 2 yr. In four other patients, the SF was measured at 2 yr only. Serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase were determined monthly for 3 mo and then every 3 or 4 mo; an elevation of transaminase was defined as > 150% of the normal upper limit in asymptomatic patients. 10 muCi of (3)H-glyco-LC (sp act 84 mCi/mol) was ingested 10-12 h before fasting duodenal biliary drainage. Bile acids in bile were separated by thin-layer chromatography. The SF was estimated as a percentage of total radioactivity (scintillation counting) in sulfated glyco-LC. The standard deviation for replicate SF determinations (n = 311) was 2.1% The pretreatment SF (mean 60.7+/-1.7 SEM) correlated inversely with age (r = 0.336, P < 0.005) and directly with the obesity index (r = 0.495, P > 0.001), but was independent of sex. The SF, remeasured at 1 or 2 yr, did not change significantly with time or CDC. Among CDC-treated patients, elevations of transaminase occurred in 75% of patients with a SF < 45% vs. 11% with a SF > 45% (P < 0.001). In conclusion, a SF < 45% occurred in patients with gallstones who had a high probability of developing elevated serum transaminase when treated with CDC. Thus, sulfation of lithocholate may modify CDC-induced elevations of serum transaminase.

MeSH Terms
Aged Alanine Transaminase/blood Aspartate Aminotransferases/blood Bile/metabolism Chenodeoxycholic Acid Cholelithiasis/enzymology Female Humans Lithocholic Acid/metabolism Male Middle Aged
Chemicals
Chenodeoxycholic Acid Lithocholic Acid Aspartate Aminotransferases Alanine Transaminase
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Marks J W
Sue S O
Pearlman B J
Bonorris G G
Varady P
Lachin J M
Schoenfield L J
References (29)
29 references, click to expand
  1. Effects of sulfation of taurolithocholic and glycolithocholic acids on their intestinal transport.
    Gastroenterology. 1969 Apr;56(4):721-6 PMID: 5821079
  2. On the turnover and excretory products of cholic and chenodeoxycholic acid in man.
    J Biol Chem. 1963 Jul;238:2299-304 PMID: 14024949
  3. Bile acid sulfates. II. Formation, metabolism, and excretion of lithocholic acid sulfates in the rat.
    J Lipid Res. 1971 Nov;12(6):680-7 PMID: 5124533
  4. A physiological method for estimation of hepatic secretion of biliary lipids in man.
    Gastroenterology. 1972 Jun;62(6):1200-17 PMID: 5050318
  5. Bile acids, liver injury, and liver disease.
    Arch Intern Med. 1972 Oct;130(4):606-17 PMID: 4627840
  6. Letter: A simple calculation of the lithogenic index of bile: expressing biliary lipid composition on rectangular coordinates.
    Gastroenterology. 1973 Oct;65(4):698-700 PMID: 4746773
  7. Influence of primary bile acid feeding on cholesterol metabolism and hepatic function in the rhesus monkey.
    Mayo Clin Proc. 1975 Mar;50(3):134-8 PMID: 1117759
  8. Letter Prevention of chenodeoxycholic-acid toxicity with lincomycin.
    Lancet. 1975 May 10;1(7915):1082 PMID: 48742
  9. Toxicity of chenodeoxycholic acid in the nonhuman primate.
    Surgery. 1975 Jun;77(6):851-60 PMID: 1145445
  10. Metabolism of lithocholate in healthy man. II. Enterohepatic circulation.
    Gastroenterology. 1975 Jul;69(1):67-76 PMID: 1097294
  11. Metabolism of lithocholate in healthy man. III. Plasma disappearance of radioactivity after intravenous injection of labeled lithocholate and its derivatives.
    Gastroenterology. 1975 Jul;69(1):77-82 PMID: 1150037
  12. Increased sulfation of lithocholate in patients with cholesterol gallstones during chenodeoxycholate treatment.
    Digestion. 1975;12(2):105-10 PMID: 1158064
  13. Hepatic toxicity in the rhesus monkey treated with chenodeoxycholic acid for 6 months: biochemical and ultrastructural studies.
    Gastroenterology. 1976 Jan;70(1):93-104 PMID: 812760
  14. Bile acids in bile during long-term chenodeoxycholic acid treatment.
    Scand J Gastroenterol. 1976;11(2):161-5 PMID: 1265436
  15. Impaired lithocholate sulfation in the rhesus monkey: a possible mechanism for chenodeoxycholate toxicity.
    Gastroenterology. 1976 Jun;70(6):1125-9 PMID: 817960
  16. Lithocholate metabolism during chenotherapy for gallstone dissolution. 1. Serum levels of sulphated and unsulphated lithocholates.
    Gut. 1976 Jun;17(6):405-12 PMID: 955495
  17. Lithocholate metabolism during chemotherapy for gallstone dissolution. 2. Absorption and sulphation.
    Gut. 1976 Jun;17(6):413-9 PMID: 955496
  18. A facile hydrolysis-solvolysis procedure for conjugated bile acid sulfates.
    J Lipid Res. 1977 Jan;18(1):118-22 PMID: 833503
  19. Chenotherapy for gallstone dissolution. I. Efficacy and safety.
    JAMA. 1978 Mar 13;239(11):1041-6 PMID: 342729
  20. Bile acid conjugation in the chimpanzee: effective sulfation of lithocholic acid.
    Arch Toxicol. 1978 Apr 27;40(2):109-18 PMID: 580732
  21. Controlled trial of chenodeoxycholic therapy for radiolucent gallstones. A multicenter study.
    Digestion. 1977;16(4):299-307 PMID: 355026
  22. Enzymatic sulphation of bile salts in human liver.
    Biochim Biophys Acta. 1978 Sep 28;530(3):451-60 PMID: 698243
  23. Nocturnal gallbladder storage and emptying in gallstone patients and healthy subjects.
    Gastroenterology. 1978 Nov;75(5):879-85 PMID: 700331
  24. Enzymatic sulphation of bile salts in man.
    Scand J Gastroenterol. 1979;14(5):513-9 PMID: 493853
  25. Effect of chenodeoxycholic acid on liver structure and function in man: a stereological and biochemical study.
    Digestion. 1980;20(1):8-21 PMID: 6766420
  26. Comparison of the effects between ursodeoxycholic and chenodeoxycholic acids on liver function and structure and bile acid composition in the Rhesus Monkey.
    Gastroenterology. 1980 Oct;79(4):629-36 PMID: 7409382
  27. Lithocholate cholestasis--sulfated glycolithocholate-induced intrahepatic cholestasis in rats.
    Gastroenterology. 1981 Feb;80(2):233-41 PMID: 7450414
  28. Design and methodological considerations in the National Cooperative Gallstone Study: a multicenter clinical trial.
    Control Clin Trials. 1981 Sep;2(3):177-229 PMID: 7326939
  29. Bile acid sulfates. I. Synthesis of lithocholic acid sulfates and their identification in human bile.
    J Lipid Res. 1971 Nov;12(6):671-9 PMID: 5124532
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1981-11-00
Pages
1190-6
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC370913
Subset
IM
Grants
NIADDK NIH HHS · 1-AM-3-2216 · United States
NIADDK NIH HHS · AM-15631 · United States
NIADDK NIH HHS · AM-19032 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com